HC Wainwright Has Pessimistic Outlook of Evotec Q2 Earnings

Key Points

• HC Wainwright cut its Q2 2026 EPS estimate for Evotec to $0.08 from $0.18, signaling a more cautious near-term earnings outlook. The firm kept a Buy rating and $7.00 price target.
• Evotec most recently reported $0.05 EPS on revenue of $297.02 million, but the company posted a negative net margin and negative return on equity. Recent coverage also suggests a wider loss and missed revenue expectations could pressure the stock.
• Despite some analyst optimism, including a few Buy ratings and a consensus Moderate Buy rating, other firms have turned more negative. Evotec shares opened at $3.07, well below the analysts’ average target price.

Evotec AG (NASDAQ:EVO - Free Report) - Analysts at HC Wainwright cut their Q2 2026 earnings estimates for Evotec in a research report issued on Thursday, May 7th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of $0.08 for the quarter, down from their prior forecast of $0.18. HC Wainwright currently has a "Buy" rating and a $7.00 target price on the stock. The consensus estimate for Evotec's current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Evotec's Q3 2026 earnings at ($0.01) EPS and FY2026 earnings at ($0.21) EPS.

Evotec (NASDAQ:EVO - Get Free Report) last released its quarterly earnings results on Tuesday, March 31st. The company reported $0.05 EPS for the quarter. Evotec had a negative net margin of 26.20% and a negative return on equity of 24.93%. The company had revenue of $297.02 million for the quarter.

Several other brokerages also recently issued reports on EVO. Berenberg Bank began coverage on shares of Evotec in a research note on Tuesday, February 3rd. They issued a "buy" rating on the stock. Weiss Ratings upgraded shares of Evotec from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, April 24th. Finally, Wall Street Zen downgraded shares of Evotec from a "hold" rating to a "sell" rating in a research note on Saturday. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $7.00.

Evotec Stock Performance

NASDAQ:EVO opened at $3.07 on Monday. The company's 50 day moving average is $2.85 and its 200-day moving average is $3.21. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.68 and a quick ratio of 1.60. Evotec has a 12 month low of $2.31 and a 12 month high of $4.80.

Institutional Investors Weigh In On Evotec

A number of institutional investors have recently bought and sold shares of the business. XTX Topco Ltd boosted its stake in Evotec by 25.1% during the fourth quarter. XTX Topco Ltd now owns 18,469 shares of the company's stock worth $57,000 after buying an additional 3,709 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in Evotec by 62.2% during the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company's stock worth $50,000 after buying an additional 4,600 shares in the last quarter. Bank of America Corp DE boosted its stake in Evotec by 262.5% during the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after buying an additional 9,289 shares in the last quarter. Apollon Wealth Management LLC acquired a new stake in Evotec during the first quarter worth $28,000. Finally, Marshall Wace LLP acquired a new stake in Evotec during the fourth quarter worth $40,000. Institutional investors and hedge funds own 5.81% of the company's stock.

Evotec News Roundup

Here are the key news stories impacting Evotec this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating on Evotec AG NASDAQ: EVO and kept a $7.00 price target, citing a path to improving earnings over the next few years.
• Positive Sentiment: The firm lifted its Q4 2026 EPS estimate to $0.01 from a prior loss expectation, suggesting improving near-term profitability.
• Neutral Sentiment: The analyst maintained relatively constructive forecasts for FY2027-FY2029, but still expects only modest earnings, with some of those estimates slightly reduced. Article Title
• Negative Sentiment: Recent earnings coverage indicated Evotec reported a wider quarterly loss and missed revenue expectations, which could weigh on the stock.

About Evotec

Evotec SE NASDAQ: EVO is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec's service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.